A Review of Existing and Emerging Treatment Interventions for Alzheimer's Disease
International Clinical Neuroscience Journal,
Vol. 11 No. 1 (2024),
4 November 2025
,
Page e6
https://doi.org/10.22037/icnj.v11i1.45042
Abstract
Cognitive decline and progressive neuropathy due to Alzheimer's disease (AD) are on the rise throughout the world today. By impairing function and reducing the affected person's quality of life, it worsens the global burden of the disease. Many treatment options are available; however, it is important to note that each has its pros and cons and should be compared side by side to develop an individualized therapeutic approach. While a few new advanced therapeutic discoveries gain traction, such as the use of polyethylene glycol (PEG)-modified black phosphorus nanosheets (BP-PEG) and revolutionary gene editing using CRISPR/Cas9, there is a need for more data available from clinical trials for a better understanding of the new techniques being worked on. Some advancements, although promising, have yet to progress from animal models to human clinical trials. A call for further investigation appears to be necessary to weigh the advantages and disadvantages of both pharmacological and non-pharmacological therapy for AD.
- Alzheimer disease, Cognitive dysfunction, Therapeutics, Pharmacology
How to Cite
References
1. Marucci G, Buccioni M, Ben DD, Lambertucci C, Volpini R, Amenta F. Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease. Neuropharmacology. 2021;190:108352. doi: 10.1016/j.neuropharm.2020.108352
2. Moreira N, De Freitas Lima JEB, Marchiori MF, Carvalho I, Sakamoto-Hojo ET. Neuroprotective effects of cholinesterase inhibitors: current scenario in therapies for Alzheimer's disease and future perspectives. J Alzheimers Dis Rep. 2022;6(1):177–193. doi: 10.3233/ADR-210061
3. Silva M, Kiametis AS, Treptow W. Donepezil inhibits acetylcholinesterase via multiple binding modes at room temperature. J Chem Inf Model. 2020;60(7):3463–3471. doi: 10.1021/acs.jcim.0c00037
4. Rajput A, Butani S. Donepezil HCl liposomes: development, characterization, cytotoxicity, and pharmacokinetic study. AAPS PharmSciTech. 2022;23(2):72. doi: 10.1208/s12249-022-02237-8
5. Durmaz L, Ertürk A, Akyüz M, Köse LP, Üç EM, Bingöl Z, et al. Screening of carbonic anhydrase, acetylcholinesterase, butyrylcholinesterase, and α-glycosidase enzyme inhibition effects and antioxidant activity of coumestrol. Molecules. 2022;27(10):3091. doi: 10.3390/molecules27103091
6. Radić Z. Shifts in backbone conformation of acetylcholinesterases upon binding of covalent inhibitors, reversible ligands and substrates. Crystals. 2021;11(12):1557. doi: 10.3390/cryst11121557
7. Kandiah N, Pai M, Senanarong V, Looi I, Ampil E, Park KW, et al. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia. Clin Interv Aging. 2017;12:697–707. doi: 10.2147/CIA.S129853
8. Silva LB, Ferreira EFB, Maryam, Espejo-Román JM, Da Costa GV, Cruz JV, et al. Galantamine-based novel acetylcholinesterase enzyme inhibitors: a molecular modeling design approach. Molecules. 2023;28(3):1035. doi: 10.3390/molecules28031035
9. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med. 2016;8(6):595–608. doi: 10.15252/emmm.201606210
10. Martins MM, Branco PS, Ferreira LM. Enhancing the Therapeutic Effect in Alzheimer's Disease Drugs: The role of Polypharmacology and Cholinesterase inhibitors. ChemistrySelect [Internet]. 2023 Mar 7;8(10). doi: 10.1002/slct.202300461
11. Liu J, Chang L, Song Y, Li H, Wu Y. The role of NMDA receptors in Alzheimer's disease. Front Neurosci. 2019;13:43. doi: 10.3389/fnins.2019.00043
12. Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, et al. Glutamate receptor ion channels: Structure, regulation, and function. Pharmacological Reviews [Internet]. 2010 Aug 17;62(3):405–96. doi: 10.1124/pr.109.002451
13. Adlard PA, James S, Bush AI, Masters CL. Beta-amyloid as a molecular therapeutic target in Alzheimer's disease. Drugs Today (Barc). 2009;45(4):293–304. doi: 10.1358/dot.2009.45.4.1366572
14. Mazer NA, Hofmann C, Lott D, Gieschke R, Klein G, Boess F, et al. Linking amyloid to clinical outcome: A quantitative semi‐mechanistic model based on the A/T/N biomarker framework to simulate the natural history of Alzheimer's disease and the effects of anti‐amyloid treatment. Alzheimer's & Dementia [Internet]. 2022;18(S3). doi: 10.1002/alz.067069
15. Karran E, De Strooper B. The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nat Rev Drug Discov. 2022;21(4):306–318. doi: 10.1038/s41573-022-00391-w
16. Żukowska J, Moss SJ, Subramanian V, Acharya KR. Molecular basis of selective amyloid-β degrading enzymes in Alzheimer's disease. FEBS J. 2023;290(22):6204–6227. doi: 10.1111/febs.16939
17. Kirschner MW. The discovery of tau protein. Cytoskeleton (Hoboken). 2023;80(12):289–293. doi: 10.1002/cm.21796
18. Abyadeh M, Gupta VK, Paulo JA, Mahmoudabad AG, Shadfar S, Mirshahvaladi S, et al. Amyloid-beta and tau protein beyond Alzheimer's disease. Neural Regen Res. 2024;19(6):1262–1276. doi: 10.4103/1673-5374.380253
19. Chen G, Grundke-Iqbal I, Iqbal K. Targeting tau protein in Alzheimer’s disease. Drugs Aging. 2010;27(5):351–365. doi: 10.2165/11536110-000000000-00000
20. Wang J, Jin WS, Bu X, Zeng F, Huang Z, Li W, et al. Physiological clearance of tau in the periphery and its therapeutic potential for tauopathies. Acta Neuropathol. 2018;136(4):525–536. doi: 10.1007/s00401-018-1891-2
21. Ma R, Li F, Guan Y, Cheng G, Song Y, Dai X, et al. Black phosphorus nanosheets as therapeutic "garbage trucks" for the selective clearance of peripheral phosphorylated tau proteins in Alzheimer's disease. Chem Eng J. 2024;150193. doi: 10.1016/j.cej.2024.150193
22. Zhang W, Xiao D, Mao Q, Xia H. Role of neuroinflammation in neurodegeneration development. Signal Transduct Target Ther. 2023;8(1):330. doi: 10.1038/s41392-023-01486-5
23. Chu J, Zhang W, Liu Y, Gong B, Ji W, Yin T, et al. Biomaterials-based anti-inflammatory treatment strategies for Alzheimer's disease. Neural Regen Res. 2024;19(1):100–115. doi: 10.4103/1673-5374.370527
24. Ross SD, Ziegert N, Rodriguez FS. Implementation of non-pharmacological interventions in dementia care: family caregiver perspective. Home Health Care Manag Pract. 2023;36(1):20–30. doi: 10.1177/10848223231174226
25. Bahar-Fuchs A, Martyr A, Goh A, Sabatés J, Clare L. Cognitive training for people with mild to moderate dementia: a Cochrane review. BJPsych Adv. 2020;26(2):66–68. doi: 10.1192/bja.2019.67
26. González-Moreno J, Satorres E, Soria-Urios G, Meléndez JC. Cognitive stimulation in moderate Alzheimer's disease. J Appl Gerontol. 2022;41(8):1934–1941. doi: 10.1177/07334648221089283
27. Bhardwaj S, Kesari KK, Rachamalla M, Mani S, Ashraf GM, Jha SK, et al. CRISPR/Cas9 gene editing: new hope for Alzheimer's disease therapeutics. J Adv Res. 2022;40:207–221. doi: 10.1016/j.jare.2021.09.002
28. Bettens K, Sleegers K, Van Broeckhoven C. Genetic insights in Alzheimer's disease. Lancet Neurol. 2013;12(1):92–104. doi: 10.1016/S1474-4422(12)70259-4
29. Duan Y, Lyu L, Zhan S. Stem cell therapy for Alzheimer's disease: a scoping review for 2017–2022. Biomedicines. 2023;11(1):120. doi: 10.3390/biomedicines11010120
30. Hayashi Y, Lin HT, Lee CC, Tsai K. Effects of neural stem cell transplantation in Alzheimer's disease models. J Biomed Sci. 2020;27(1):29. doi: 10.1186/s12929-020-0622-x
31. Chang J, Li Y, Shan X, Chen X, Yan X, Liu J, et al. Neural stem cells promote neuroplasticity: a promising therapeutic strategy for the treatment of Alzheimer's disease. Neural Regen Res. 2024;19(3):619–628. doi: 10.4103/1673-5374.380263
32. Laxton AW, Stone S, Lozano AM. The neurosurgical treatment of Alzheimer's disease: a review. Stereotact Funct Neurosurg. 2014;92(5):269–281. doi: 10.1159/000362936
33. Fontaine D, Santucci S. Deep brain stimulation in Alzheimer's disease. In: International Review of Neurobiology. Vol. 159. Amsterdam: Elsevier; 2021. p. 69–87. doi: 10.1016/bs.irn.2021.07.006
34. McDermott B, Porter E, Hughes D, McGinley B, Lang MJ, O'Halloran M, et al. Gamma band neural stimulation in humans and the promise of a new modality to prevent and treat Alzheimer's disease. J Alzheimers Dis. 2018;65(2):363–392. doi: 10.3233/JAD-180391
35. Mannu P, Rinaldi S, Fontani V, Castagna A. Radio electric asymmetric brain stimulation in the treatment of behavioral and psychiatric symptoms in Alzheimer disease. Clin Interv Aging. 2011;6:207–211. doi: 10.2147/CIA.S16371
36. Liu X, Naomi SSM, Sharon WL, Russell E. The applications of focused ultrasound (FUS) in Alzheimer's disease treatment: a systematic review on both animal and human studies. Aging Dis. 2021;12(8):1977–1993. doi: 10.14336/AD.2021.0510
- Abstract Viewed: 116 times
- PDF Downloaded: 74 times